Staar Surgical CO STAA
We take great care to ensure that the data presented and summarized in this overview for STAAR SURGICAL CO is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding STAA
View all-
Broadwood Capital Inc New York, NY13.5MShares$356 Million21.93% of portfolio
-
Black Rock Inc. New York, NY7.49MShares$197 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.27MShares$112 Million0.0% of portfolio
-
Yunqi Capital LTD Hong Kong, K32.5MShares$65.8 Million53.11% of portfolio
-
State Street Corp Boston, MA1.91MShares$50.3 Million0.0% of portfolio
-
Balyasny Asset Management LLC Chicago, IL1.81MShares$47.7 Million0.07% of portfolio
-
Magnetar Financial LLC Evanston, IL1.2MShares$31.7 Million1.14% of portfolio
-
Geode Capital Management, LLC Boston, MA1.17MShares$30.9 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY976KShares$25.7 Million0.0% of portfolio
-
Alpine Associates Management Inc. Englewood Cliffs, NJ913KShares$24 Million1.54% of portfolio
Latest Institutional Activity in STAA
Top Purchases
Top Sells
About STAA
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Insider Transactions at STAA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 21
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
|
Nov 21
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
797,486
+5.04%
|
$21,532,122
$27.86 P/Share
|
|
Nov 20
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
|
Nov 20
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
393,382
+2.69%
|
$10,621,314
$27.14 P/Share
|
|
Nov 19
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
|
Nov 19
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
309,132
+2.19%
|
$8,037,432
$26.42 P/Share
|
|
Nov 12
2025
|
Wei Jiang |
BUY
Exercise of conversion of derivative security
|
Direct |
20,967
+31.56%
|
-
|
|
Aug 12
2025
|
Wei Jiang |
BUY
Exercise of conversion of derivative security
|
Direct |
20,967
+46.1%
|
-
|
|
May 08
2025
|
Magda Michna Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,675
-10.39%
|
$31,825
$19.53 P/Share
|
|
Apr 10
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
|
Apr 10
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
900
+0.01%
|
$13,500
$15.18 P/Share
|
|
Apr 09
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
|
Apr 09
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
8,200
+0.06%
|
$123,000
$15.08 P/Share
|
|
Apr 08
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
|
Apr 08
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
178,127
+0.65%
|
$2,671,905
$15.62 P/Share
|
|
Apr 07
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
|
Apr 07
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
138,054
+0.51%
|
$2,070,810
$15.78 P/Share
|
|
Apr 04
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
|
Apr 04
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
497,631
+1.82%
|
$7,962,096
$16.18 P/Share
|
|
Apr 03
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 100K shares |
|---|---|
| Open market or private purchase | 4.25M shares |
| Payment of exercise price or tax liability | 17.2K shares |
|---|